Xenon Pharmaceuticals Inc. (XENE) NASDAQ
52.30
-1.11(-2.08%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Xenon Pharmaceuticals Inc.
Sector
Healthcare
Industry
Biotechnology
Employees
316
First IPO Date
November 05, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Ian C. Mortimer | President, Chief Executive Officer & Director | 1.38M | 1976 |
| James R. Empfield | Executive Vice President of Drug Discovery | 323,428 | 1961 |
| Thomas Patrick Kelly | Chief Financial Officer | 515,697 | 1971 |
| Robin Sherrington | Executive Vice President of Strategy & Innovation | 587,028 | 1961 |
| Darren S. Cline | Chief Commercial Officer | 619,768 | 1964 |
| Andrea DiFabio | Chief Legal Officer & Corporate Secretary | 766,152 | 1968 |
| Christopher John Kenney | Chief Medical Officer | 848,652 | 1971 |
| Gilbert | Senior Director | 0 | N/A |
| Shelley McCloskey | Executive Vice President of Human Resources | 0 | 1960 |
| Matthew D. Ronsheim | Chief Operating Officer | 0 | 1973 |
| Colleen Alabiso | Senior Vice President of Corporate Affairs | 0 | N/A |
| Shelley McClCoskey | Executive Vice President of Human Resources | 0 | 1960 |
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
